



February 5, 2009

ANGIOTECH'S CORPORATE PARTNER, BOSTON SCIENTIFIC, SUBMITS FINAL MODULES TO FDA FOR APPROVAL OF SECOND-GENERATION SMALL VESSEL AND LONG LESION STENTS

Journal of American College of Cardiology publishes positive ATLAS clinical data

VANCOUVER, BC, February 5, 2009 – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that its corporate partner, Boston Scientific, has submitted the final modules for pre-market approval (PMA) for both its TAXUS[®] Liberté[®] Atom[™] Paclitaxel-Eluting Coronary Stent System and its TAXUS[®] Liberté Long[™] Paclitaxel-Eluting Coronary Stent System to the U.S. Food and Drug Administration (FDA). If approved, the TAXUS Liberté Atom Stent will become Boston Scientific's second 2.25 mm diameter drug-eluting stent (DES) available in the United States. It will then likely succeed the TAXUS Express[™] Atom Stent, which is Boston Scientific's first approved small stent and the only DES currently approved by the FDA to treat small vessels. The TAXUS Liberté Long Stent is designed to be the first 38 mm drug-eluting stent available in the U.S. and will further expand this leading DES portfolio.

“We are pleased to have a second-generation small vessel DES and the U.S. market's first long DES under review by the FDA,” said Jim Tobin, President and Chief Executive Officer of Boston Scientific. “The rapid adoption of our recently approved TAXUS Express Atom Stent confirms the need for an expanded DES size matrix to treat the wide range of vessel anatomies seen in daily clinical practice.”

These PMA submissions include clinical data from the global, multi-center TAXUS ATLAS Small Vessel (SV) and Long Lesion (LL) studies, designed to compare the performance of the TAXUS Liberté Atom and TAXUS Liberté Long Stents with Boston Scientific's first-generation TAXUS Express Stent. While the second-generation TAXUS Liberté Stent uses identical drug dose, polymer and release kinetics as the TAXUS Express Stent, it features thinner struts and a uniform architecture specifically designed for drug delivery.

One-year results from the TAXUS ATLAS SV and LL studies were published in the December 2008 issue of the Journal of American College of Cardiology. The studies both met their primary endpoint of non-inferior, nine-month, in-segment diameter stenosis versus the TAXUS Express Stent control group. They reported a significant reduction in small vessel in-stent restenosis and major adverse coronary events (MACE) in patients treated with the TAXUS Liberté Atom Stent, and a significantly reduced rate of myocardial infarction (heart attack) in patients with long lesions treated with the TAXUS Liberté Long Stent.

“In the ATLAS study, lower target lesion revascularization (TLR) rates contributed to a significantly lower rate of MACE, including heart attacks, with the TAXUS Liberté Atom Stent,” said Mark A. Turco, M.D., Director of the Center for Cardiac and Vascular Research, Washington Adventist Hospital, and Co-Principal Investigator of the ATLAS trial. “The thinner struts of the TAXUS Liberté Atom Stent are designed to improve its deliverability and conformability, which is important when treating small vessels. The TAXUS Liberté Stent also features an advanced stent cell geometry that has been designed to allow for more consistent drug distribution.”

Patients with small vessels treated with the TAXUS Liberté Atom Stent reported significantly lower nine-month angiographic in-segment late loss (0.16 mm vs. 0.32 mm, $p=0.0146$), reduced nine-month angiographic restenosis (18.5% vs. 32.7%, $p=0.0219$), reduced 12-month TLR (6.1% vs. 16.9%, $p=0.0039$), and reduced rates of stent thrombosis (0.4% vs. 1.5%, $p=0.39$). Patients with long lesions treated with the

TAXUS Liberté Long Stent reported a significantly reduced 12-month rate of myocardial infarction (1.4% vs. 6.5%, $p=0.0246$) as well as a trend toward fewer stent thromboses (0% vs. 0.7%, $p=0.48$).

Boston Scientific remains the overall drug-eluting stent market leader in the United States, with a 49 percent share of the market in December. The Company released three major DES products in the United States in 2008 including the TAXUS Express Atom Stent and the TAXUS Liberté Stent. Boston Scientific expects to launch its third-generation drug-eluting stents, including the TAXUS Element™ Paclitaxel-Eluting Coronary Stent, in Europe later this year.

The TAXUS Liberté Atom, TAXUS Liberté Long and TAXUS Element stents are investigational devices and are restricted under U.S. law to investigational use only.

Forward Looking Statements

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words “believes,” “may,” “plans,” “will,” “estimate,” “continue,” “anticipates,” “intends,” “expects” and similar expressions, constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the “safe harbor” provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the fourth quarter of 2008 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission (“SEC”) and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the “Risk Factors” section in our annual report for the year ended December 31, 2007 filed with the SEC on Form 40-F and our quarterly report for the three months ended September 30, 2008 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.

©2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

Boston Scientific Corporation acquired worldwide exclusive rights from Angiotech to use paclitaxel to coat its coronary stent products and has co-exclusive rights to certain peripheral vascular and non-vascular products.

TAXUS® Liberté® Atom™ and Long™ are registered trademarks of Boston Scientific Corporation.

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.

FOR ADDITIONAL INFORMATION:

DeDe Sheel, Investor Relations and Corporate Communications
Angiotech Pharmaceuticals, Inc.
(415) 293-4412
dede.sheel@fdashtonpartners.com